News | June 30, 2024
Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals
Laurus Labs receives EIR from USFDA for API facilities
Laurus Labs receives EIR from USFDA for API facilities
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
The registered capital of the newly founded company is € 50 million
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Subscribe To Our Newsletter & Stay Updated
